stock.name

Agios Pharmaceuticals Inc

AGIO

Market Cap$1.7B
Close$

Compare Agios Pharmaceuticals

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Agios Pharmaceuticals IncAgios Pharmaceuticals Inc1.10%115%--
marketMarket Avg59.61.27%31%6.41
HealthcareHealthcare Avg62.31.27%15%7.30.9
$32.82

Current Fair Value

12.7% upside

Undervalued by 12.7% based on the discounted cash flow analysis.

Share Statistics

Market cap$1.70 Billion
Enterprise Value$433.69 Million
Dividend Yield$0.0 (0.0%)
Earnings per Share$24.93
Beta1.11
Outstanding Shares56,194,847
Avg 30 Day Volume921,427

Return

Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio1.06
PEG-10.28
Price to Sales-
Price to Book Ratio1.21
Enterprise Value to Revenue9.85
Enterprise Value to EBIT-1.18
Enterprise Value to Net Income0
Total Debt to Enterprise0
Debt to Equity0

Revenue Sources

No data

ESG Score

No data

About Agios Pharmaceuticals Inc

536 employees
CEO: Jacqualyn Fouse

Agios Pharmaceuticals Inc. is a public American pharmaceutical company focused on developing small-molecule anti-cancer therapeutics targeting cancer cell metabolism via the growth factor pathway. Among the proteins under investigation b...